ElectroCore, Inc. Announces Revenue Guidance for the Full Year 2020
January 11, 2021 at 01:17 pm
Share
electroCore, Inc. announced revenue Guidance for the Full year 2020. For the period, the company expected revenue at the upper end of previously announced guidance range of $3.3 Million to $3.5 Million; greater than 40% growth over full year 2019 revenue of $2.4 Million.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company. It provides non-invasive vagus nerve stimulation (nVNS) technology platform. The Companyâs product categories include Handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headache, and Handheld, personal use consumer products utilizing nVNS technology to promote general wellness and human performance. Its products include gammaCore, Truvaga and TAC-STIM. Its gammaCore Sapphire, is a prescription medical device that is used for a variety of primary headache conditions. Its Truvaga is a personal use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com. The Companyâs TAC-STIM product is not a medical device and is not intended to diagnose, cure, mitigate, prevent, or treat a disease or condition.
ELECTROCORE, INC. 
